{"paper_id":"59715d14-045b-4506-a95e-e3c7ad123f97","body_text":"Effects of kuntai capsule in combination with hormone replacement therapy on premature ovarian failure and bone metabolism\n(1) Center for Bone Joint, Jiangyin Clinical College, Xuzhou Medical University, Jiangsu Province, China\n(2) Center for Bone Joint, Jiangyin Clinical College, Xuzhou Medical University, Jiangsu Province, China\n(3) Department of Gynecology, Jiangyin Clinical College, Xuzhou Medical University, Jiangsu Province, China\n(4) Department of Gynecology, Jiangyin Clinical College, Xuzhou Medical University, Jiangsu Province, China\n(5) Department of Gynecology, Jiangyin Clinical College, Xuzhou Medical University, Jiangsu Province, China\nCorresponding Author\nAbstract\nReferences\nSzeliga A, Calik-Ksepka A, Maciejewska-Jeske M,\nGrymowicz M, Smolarczyk K, Kostrzak A,\nSmolarczyk R, Rudnicka E and Meczekalski B.\nAutoimmune Diseases in Patients with Premature\nOvarian Insufficiency-Our Current State of\nKnowledge. Int J Mol Sci 2021, 22(5).\nWang J, Sun X, Yang Z, Li S, Wang Y, Ren R, Liu Z and Yu\nD. Epigenetic regulation in premature ovarian failure:\nA literature review. Front Physiol 2022, 13(998424.\nBai X and Wang S. Signaling pathway intervention in\npremature ovarian failure. Front Med (Lausanne)\n, 9(999440.\nChon SJ, Umair Z and Yoon MS. Premature Ovarian\nInsufficiency: Past, Present, and Future. Front Cell\nDev Biol 2021, 9(672890.\nLi Z, Qi H, Li Z, Bao Y, Yang K and Min Q. Research\nprogress on the premature ovarian failure caused by\ncisplatin therapy. Front Oncol 2023, 13(1276310.\nWang Y, Jiang J, Zhang J, Fan P and Xu J. Research Progress\non the Etiology and Treatment of Premature Ovarian\nInsufficiency. Biomed Hub 2023, 8(1):97-107.\nSvejme O, Ahlborg HG, Nilsson JA and Karlsson MK. Early\nmenopause and risk of osteoporosis, fracture and\nmortality: a 34-year prospective observational study\nin 390 women. BJOG 2012, 119(7):810-816.\nSamak MA, Abdelrahman AA, Samy W, Abdelrahman SA.\nCombined Bazedoxifene and Genistein Ameliorate\nOvariectomy-Induced\nHippocampal\nAlterations\nvia\nNeuro\nActivating CREB/BDNF/TrkB\nSignaling\nPathway. Curr Mol Pharmacol.\n;16(6):664-681.\nSullivan SD, Sarrel PM and Nelson LM. Hormone\nreplacement therapy in young women with primary\novarian insufficiency and early menopause. Fertil\nSteril 2016, 106(7):1588-1599.\nZhang S, Wang L, Zhang J, An W and Jia L. The efficacy\nand safety of Kuntai capsule combined with\nleuprorelin acetate in the treatment of endometriosis:\nA protocol for systematic review and meta-analysis.\nMedicine (Baltimore) 2021, 100(11):e25080.\nZhang J, Fang L, Shi L, Lai Z, Lu Z, Xiong J, Wu M, Luo\nA and Wang S. Protective effects and mechanisms\ninvestigation of Kuntai capsule on the ovarian\nfunction of a novel model with accelerated aging\novaries. J Ethnopharmacol 2017, 195(173-181.\nGao H, Xia T, Ma R, Zhao ZORC, Wang B, Song X, Liu L,\nHan K, Wang G, Fu Y and Hao G. Heyan Kuntai\ncapsule versus dehydroepiandrosterone in treating\nChinese patients with infertility caused by diminished\novarian reserve: a multicenter, randomized controlled\ntrial. J Tradit Chin Med 2017, 37(4):530-537.\nLiu FX and Sun Y. Identification of the active ingredients\nand pharmacological effects of Kuntai capsules in the\ntreatment of primary ovarian insufficiency: A review.\nMedicine (Baltimore) 2023, 102(21):e33884.\nMa Q, Tan Y and Mo G. Effectiveness of Cotreatment with\nKuntai Capsule and Climen for Premature Ovarian\nFailure: A Meta-Analysis. Evid Based Complement\nAlternat Med 2020, 2020(4367359.\nZhang X, Zhang L, Xiong L, Liu X, Zhang J, Yu F, Li Y,\nChang W and Chen W. Kuntai capsule for the\ntreatment of diminished ovarian reserve: A\nsystematic review and meta-analysis of randomized\ncontrolled trials. J Ethnopharmacol 2024, 329(118167.\nTang X, Huang Q, Wang C, Zhang D, Dong S and Yu C.\nKuntai Capsule Combined With Letrozole on\nGonadal Hormone Levels and Ovarian Function in\nPatients With PCOS: A Systematic Review and\nMeta-Analysis. Front Endocrinol (Lausanne) 2021,\n(789909.\nZhong HZ, Li MY, Yin XL, Bin CL, Zhou SY and Wei SB.\nChinese patent medicines combined with hormone\nreplacement therapy for premature ovarian failure: A\nBayesian network meta-analysis. Front Med\n(Lausanne) 2022, 9(1043390.\nCai L, Zong DK, Tong GQ and Li L. Apoptotic mechanism\nof premature ovarian failure and rescue effect of\nTraditional Chinese Medicine: a review. J Tradit\nChin Med 2021, 41(3):492-498.\nPargianas M, Salta S, Apostolopoulou K, Lazaros L,\nKyrgiou M, Tinelli A, Malvasi A, Kalogiannidis I,\nGeorgiou I and Kosmas IP. Pathways Involved in\nPremature Ovarian Failure: A Systematic Review of\nExperimental Studies. Curr Pharm Des 2020,\n(18):2087-2095.\nFreitas ATA, Donovan Giraldo AE, Pravatta Rezende G,\nYela DA, Jales RM and Benetti-Pinto CL. Body\ncomposition in women with premature ovarian\ninsufficiency using hormone therapy and the relation\nto cardiovascular risk markers: A case-control study.\nClin Endocrinol (Oxf) 2021, 94(1):111-118.\nPolakova M. Specifics of infertility treatment in women\nwith premature ovarian failure. Ceska Gynekol 2023,\n(2):131-134.\nLin J, Li XL, Song H, Li Q, Wang MY, Qiu XM, Li DJ and\nWang L. A general description for Chinese medicine\nin treating premature ovarian failure. Chin J Integr\nMed 2017, 23(2):91-97.\nChen H, Zhang G, Peng Y, Wu Y, Han X, Xie L, Xu H,\nChen G, Liu B, Xu T, Pang M, Hu C, Fan H, Bi Y,\nHua Y, Zhou Y and Luo S. Danggui Shaoyao San\nprotects\ncyclophosphamide-induced\npremature\novarian failure by inhibiting apoptosis and oxidative\nstress through the regulation of the SIRT1/p53\nsignaling pathway. J Ethnopharmacol 2024,\n(117718.\nSato T, Kusuhara A, Kasahara Y, Haino T, Kishi H and\nOkamoto A. Follicular development during hormone\nreplacement therapy in patients with premature\novarian insufficiency. Reprod Med Biol 2021,\n(2):234-240.\nHamoda H and Sharma A. Premature ovarian insufficiency,\nearly menopause, and induced menopause. Best Pract\nRes Clin Endocrinol Metab 2024, 38(1):101823.\nCraciunas L, Zdoukopoulos N, Vinayagam S and\nMohiyiddeen L. Hormone therapy for uterine and\nendometrial development in women with premature\novarian insufficiency. Cochrane Database Syst Rev\n, 10(10):CD008209.\nDing X, Lv S, Guo Z, Gong X, Wang C, Zhang X and Meng\nK. Potential Therapeutic Options for Premature\nOvarian Insufficiency: Experimental and Clinical\nEvidence. Reprod Sci 2023, 30(12):3428-3442.\nGenazzani AR, Monteleone P, Giannini A and Simoncini T.\nHormone therapy in the postmenopausal years:\nconsidering benefits and risks in clinical practice.\nHum Reprod Update 2021, 27(6):1115-1150.\nLi WJ, Xu LZ, Liu HW, Zhang J, Tang LL, Zhou LL,\nZhuang J, Liu Y and Liu XF. [Effects of Kuntai\nCapsule and hormone replacement therapy on\ncognitive function and mental symptoms of early\npostmenopausal women: a randomized controlled\ntrial]. Zhong Xi Yi Jie He Xue Bao 2010, 8(4):321\nZhou Q, Tao J, Song H, Chen A, Yang H, Zuo M and Li H.\nChinese herbal medicine Kuntai capsule for treatment\nof menopausal syndrome: a systematic review of\nrandomized clinical trials. Complement Ther Med\n, 29(63-71.\nLiang R, Liu Z, Li P, Fan P, Xu L, Sun X, Peng J, Peng X\nand Zhang M. Kuntai capsules improve glucolipid\nmetabolism in patients with polycystic ovary\nsyndrome: A randomized, double-blind, placebo\ncontrolled trial. Medicine (Baltimore) 2019,\n(39):e16788.\nQi X, Guo Y and Sun L. Effects of Kuntai capsule on breast\npain and vaginal bleeding in postmenopausal women.\nPak J Pharm Sci 2019, 32(5(Special)):2471-2476.\nArticle Metrics\nAbstract View : 1716 timesPDF Download : 535 times\nRefbacks\n- There are currently no refbacks.","source_license":"CC0","license_restricted":false}